{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T03:14:27Z","timestamp":1722914067672},"reference-count":39,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med Report"],"DOI":"10.3892\/mmr.2017.7922","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T10:15:56Z","timestamp":1509099356000},"source":"Crossref","is-referenced-by-count":2,"title":["Genetically engineered recombinant adenovirus expressing interleukin\u20112 for hepatocellular carcinoma therapy"],"prefix":"10.3892","author":[{"given":"Yunpeng","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaming","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqi","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"key20200713222951_b1-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.jhep.2004.11.014","article-title":"Management of patients with hepatitis B virus-induced cirrhosis","volume":"42","author":"Fung","year":"2005","journal-title":"J Hepatol"},{"key":"key20200713222951_b2-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1365-2036.2006.02704.x","article-title":"Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter","volume":"23","author":"Huang","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key20200713222951_b3-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1055\/s-2004-813669","article-title":"Long-term results of interventional treatment of large unresectable hepatocellular carcinoma (HCC): Significant survival benefit from combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) compared to TACE monotherapy","volume":"176","author":"Lubienski","year":"2004","journal-title":"Rofo"},{"key":"key20200713222951_b4-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.kjms.2014.11.003","article-title":"Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma","volume":"31","author":"Yeh","year":"2015","journal-title":"Kaohsiung J Med Sci"},{"key":"key20200713222951_b5-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/pbc.25508","article-title":"Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy","volume":"62","author":"Marabelle","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"key20200713222951_b6-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/cas.12650","article-title":"Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses","volume":"106","author":"Nishimura","year":"2015","journal-title":"Cancer Sci"},{"key":"key20200713222951_b7-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"key20200713222951_b8-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-015-1672-x","article-title":"Intravesical chitosan\/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer","volume":"64","author":"Smith","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713222951_b9-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1134\/S0026893315020028","article-title":"Expressing foreign genes by Newcastle disease virus for cancer therapy","volume":"49","author":"Bai","year":"2015","journal-title":"Mol Biol (Mosk)"},{"key":"key20200713222951_b10-mmr-17-01-0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000436998","article-title":"Immunotherapy of Melanoma","volume":"42","author":"Snyder","year":"2015","journal-title":"Prog Tumor Res"},{"key":"key20200713222951_b11-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.4161\/cbt.29686","article-title":"Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy","volume":"15","author":"Bai","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"key20200713222951_b12-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00262-012-1289-2","article-title":"Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer","volume":"61","author":"Shi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713222951_b13-mmr-17-01-0300","first-page":"7728","article-title":"Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy","volume":"8","author":"Chen","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"key20200713222951_b14-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: A systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20200713222951_b15-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.3748\/wjg.v17.i16.2143","article-title":"p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up","volume":"17","author":"Guan","year":"2011","journal-title":"World J Gastroenterol"},{"key":"key20200713222951_b16-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/hep.20613","article-title":"Combined endostatin\/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC","volume":"41","author":"Graepler","year":"2005","journal-title":"Hepatology"},{"key":"key20200713222951_b17-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.onc.1207033","article-title":"A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent","volume":"23","author":"Zou","year":"2004","journal-title":"Oncogene"},{"key":"key20200713222951_b18-mmr-17-01-0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1665-2681(19)31948-9","article-title":"Gene therapy of liver cancer","volume":"6","author":"Hern\u00e1ndez-Alcoceba","year":"2007","journal-title":"Ann Hepatol"},{"key":"key20200713222951_b19-mmr-17-01-0300","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3892\/ol.2012.987","article-title":"Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma","volume":"5","author":"Yan","year":"2013","journal-title":"Oncol Lett"},{"key":"key20200713222951_b20-mmr-17-01-0300","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4049\/jimmunol.112.1.420","article-title":"Purification of human T and B lymphocytes","volume":"112","author":"Greaves","year":"1974","journal-title":"J Immunol"},{"key":"key20200713222951_b21-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/gt.2009.14","article-title":"Genetically engineered Newcastle disease virus for malignant melanoma therapy","volume":"16","author":"Zamarin","year":"2009","journal-title":"Gene Ther"},{"key":"key20200713222951_b22-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1007\/s00005-008-0047-9","article-title":"Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers","volume":"56","author":"Sinkovics","year":"2008","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"key20200713222951_b23-mmr-17-01-0300","first-page":"671","article-title":"Inhibition of adenovirus-mediated gene transfer of antisense matrix metalloproteinase-2 on hepatocellular carcinoma growth in vivo","volume":"13","author":"Zhang","year":"2005","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"key20200713222951_b24-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1089\/cbr.2006.21.225","article-title":"Oncolytic adenovirus-mediated E1A gene therapy induces tumor-cell apoptosis and reduces tumor angiogenesis leading to inhibition of hepatocellular carcinoma growth in animal model","volume":"21","author":"Ye","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"key20200713222951_b25-mmr-17-01-0300","first-page":"461","article-title":"Inhibition of hepatocellular carcinoma growth by adenovirus-mediated mda-7 with adriamycin","volume":"16","author":"Hu","year":"2008","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"key20200713222951_b26-mmr-17-01-0300","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3892\/ol.2013.1470","article-title":"Inhibition of hepatocellular carcinoma growth by adenovirus-mediated expression of human telomerase reverse transcriptase COOH-27 terminal polypeptide in mice","volume":"6","author":"He","year":"2013","journal-title":"Oncol Lett"},{"key":"key20200713222951_b27-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/PPO.0b013e3182431a73","article-title":"Immunotherapy for the treatment of glioblastoma","volume":"18","author":"Thomas","year":"2012","journal-title":"Cancer J"},{"key":"key20200713222951_b28-mmr-17-01-0300","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1684\/bdc.2011.1352","article-title":"Cellular immunotherapy and glioblastoma: A hopeful treatment?","volume":"98","author":"Larsen","year":"2011","journal-title":"Bull Cancer"},{"key":"key20200713222951_b29-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1158\/0008-5472.CAN-07-0674","article-title":"Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses","volume":"67","author":"Varghese","year":"2007","journal-title":"Cancer Res"},{"key":"key20200713222951_b30-mmr-17-01-0300","first-page":"3649","article-title":"Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy","volume":"58","author":"Husain","year":"1998","journal-title":"Cancer Res"},{"key":"key20200713222951_b31-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nbt0598-449","article-title":"Novel anti-brain tumor cytotoxins specific for cancer cells","volume":"16","author":"Debinski","year":"1998","journal-title":"Nat Biotechnol"},{"key":"key20200713222951_b32-mmr-17-01-0300","first-page":"4018","article-title":"Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2","volume":"59","author":"Bera","year":"1999","journal-title":"Cancer Res"},{"key":"key20200713222951_b33-mmr-17-01-0300","first-page":"5876","article-title":"Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites","volume":"51","author":"Ghetie","year":"1991","journal-title":"Cancer Res"},{"key":"key20200713222951_b34-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/jso.23897","article-title":"Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma","volume":"111","author":"Wang","year":"2015","journal-title":"J Surg Oncol"},{"key":"key20200713222951_b35-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00262-003-0490-8","article-title":"Further development of local IL-2 therapy of cancer: Multiple versus single IL-2 treatment of transplanted murine colon carcinoma","volume":"53","author":"Kusnierczyk","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"key20200713222951_b36-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11934-001-0019-7","article-title":"Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer","volume":"2","author":"Pantuck","year":"2001","journal-title":"Curr Urol Rep"},{"key":"key20200713222951_b37-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/cmi.2014.40","article-title":"Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: A phase I\/II trial","volume":"12","author":"Baek","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"key20200713222951_b38-mmr-17-01-0300","first-page":"1993","article-title":"IL-2 gene therapy of advanced lung cancer patients","volume":"16","author":"Tan","year":"1996","journal-title":"Anticancer Res"},{"key":"key20200713222951_b39-mmr-17-01-0300","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.imlet.2014.02.009","article-title":"Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy","volume":"159","author":"Bai","year":"2014","journal-title":"Immunol Lett"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T17:41:20Z","timestamp":1693158080000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mmr.2017.7922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":39,"URL":"https:\/\/doi.org\/10.3892\/mmr.2017.7922","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]}}}